12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

AthernoNova, Maxwell Biotech preclinical data

In a mouse model of atherosclerosis, AHRO-001 plus chow for 15 weeks reduced fasting plasma glucose (FPG) levels by 37% vs. chow alone. AHRO-001 plus chow also significantly reduced atherosclerotic lesion size at the...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >